BioSpace News Archive

elicity, a proprietary telehealth platform powered by InTeleLabs® Inc., is now offering the first COVID-19 Antibody test to receive an Emergency Use Authorization (EUA) that allows patients to collect dried blood spot samples at home

Cardinal Health was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services could reach $91.6 million, for the storage and distribution of 80,000 pallets of personal protective equipment to support the Strategic National Stockpile, part of the Office of the Assistant Secretary for Preparedness and Response within HHS.

Aphex BioCleanse Systems, Inc. (OTCPK: SNST) (“Aphex” or “the Company”), a sanitization solutions company focused on the development and distribution of non-toxic and water-based sanitization and disinfection products trademarked as Hy-IQ® Water, announced today that world-renowned entrepreneur Mark Timm has joined the Company as Chief Marketing Officer and Member of the Board.

MercuryGate® International, Inc., (MercuryGate) the largest, dedicated transportation management system (TMS) provider today announced it has been recognized as a Challenger in the March 2021 Gartner Magic Quadrant for Transportation Management Systems (TMS).

Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology

Multi-targeted oral candidate with the potential to be a first-line treatment option for adult and pediatric patients with NASH Phase 2b clinical trial in adults expected to begin in Q2

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced the installation of its 500th unit, achieving a key milestone set forth when the Company began operations in February 2011.

This Pre-Series A Funding will accelerate the growth of ImpriMed’s AI-powered predictive tool that identifies which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia